BERKELEY, CA (UroToday.com) - New blood vessels are formed from preexisting capillaries during tumor development. This process, widely known as tumor angiogenesis, sustains tumor progression under pathological conditions. The molecules involved in tumor angiogenesis are potential biomarkers and targets of pharmacological intervention.[1, 2] An anti-vascular endothelial growth factor (VEGF) treatment used in patients with metastatic colon cancer validates the therapeutic value of tumor antiangiogenic intervention.[3, 4] Inhibition of VEGF-dependent angiogenesis combined with chemotherapy is clearly effective under some pathological conditions; however, its effectiveness is limited[5, 6] suggesting that the characterization of alternative molecular new targets is essential for developing novel antiangiogenic therapeutic tools. Several theoretical factors have been used for targeting tumor vasculatures as anticancer strategies. We previously reported that tumor endothelial cells (TECs) differ from normal endothelial cells (NECs) in terms of characteristics such as cell proliferation, migration, gene profile, and responses to growth factors[7, 8] or various chemotherapeutic drugs. Furthermore, TECs were cytogenetically abnormal.